^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DYP688

    i
    Other names: DYP688, DYP-688, DYP 688
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    GNAQ inhibitor, GNA11 antagonist, gp100-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    30d
    Uveal Melanoma: Changing Paradigms of Treatment. (PubMed, Ocul Oncol Pathol)
    In 2022, tebentafusp became the first approved systemic therapy to improve overall survival in metastatic UM...As half of the patients are HLA A02:01 negative, alternative strategies are under investigation, including the protein kinase C inhibitor darovasertib in the NADOM neoadjuvant/adjuvant trial and in combination with crizotinib in metastatic UM. DYP688, a first-in-class PMEL17-targeting antibody-drug conjugate that inhibits GNAQ/11 signaling, has shown promise in metastatic UM and other GNAQ/11-mutant melanomas. The landscape of UM treatment is rapidly evolving following the identification of new targets and pathways such as PKC or PRAME. Combination of liver-directed therapies with personalized systemic immunotherapies or targeted agents in the metastatic disease, as well as the early use of systemic therapies in the primary tumor setting will refine treatment strategies in UM and suggest improved outcomes in the near future.
    Review • Journal • IO biomarker
    |
    GNAQ (G Protein Subunit Alpha Q) • PRAME (Preferentially Expressed Antigen In Melanoma) • PMEL (Premelanosome Protein)
    |
    Xalkori (crizotinib) • darovasertib (IDE196) • Kimmtrak (tebentafusp-tebn) • DYP688
    9ms
    A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
    P1/2, N=66, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=124 --> 66 | Trial completion date: Sep 2025 --> Oct 2027 | Trial primary completion date: Sep 2025 --> Oct 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    GNAQ (G Protein Subunit Alpha Q)
    |
    DYP688
    almost2years
    A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
    P1/2, N=124, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Mar 2026 --> Sep 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    GNAQ (G Protein Subunit Alpha Q)
    |
    DYP688
    over3years
    A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
    P1/2, N=124, Recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    GNAQ (G Protein Subunit Alpha Q)
    |
    DYP688
    over3years
    A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the body (clinicaltrialsregister.eu)
    P1/2, N=124, Novartis Pharma AG
    New P1/2 trial
    |
    GNAQ (G Protein Subunit Alpha Q)
    |
    DYP688
    over3years
    A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
    P1/2, N=124, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GNAQ (G Protein Subunit Alpha Q)
    |
    DYP688
    almost4years
    A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
    P1/2, N=124, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    GNAQ (G Protein Subunit Alpha Q)
    |
    DYP688